Abstract
We examined paclitaxel for anti‐tumor activity against human lung cancer xenografts in nude mice and compared its efficacy with that of cisplatin, currently a key drug for lung cancer chemotherapy. Five non‐small cell lung cancers (A549, NCI‐H23, NCI‐H226, NCI‐H460 and NCI‐H522) and 2 small cell lung cancers (DMS114 and DMS273) were chosen for this study, since these cell lines have been well characterized as regards in vitro and in vivo drug sensitivity. These cells were exposed to graded concentrations of paclitaxel (0.1 to 1000 nM) for 48 h. The 50% growth‐inhibitory concentrations (GI50) for the cell lines ranged from 4 to 24 nM, which are much lower than the achievable peak plasma concentration of paclitaxel. In the in vivo study, 4 cell lines (A549, NCI‐H23, NCI‐H460, DMS‐273) were grown as subcutaneous tumor xenografts in nude mice. Paclitaxel was given intravenously as consecutive daily injections for 5 days at the doses of 24 and 12 mg/kg/day. Against every xenograft, paclitaxel produced a statistically significant tumor growth inhibition compared to the saline control. Paclitaxel at 24 mg/kg/day was more effective than cisplatin at 3 mg/kg/day with the same dosing schedule as above, although the toxicity of paclitaxel was similar to or rather lower than that of cisplatin, in terms of body weight loss. In addition, paclitaxel showed potent activity against 2 other lung cancer xenografts (NCI‐H226 and DMS114). Therefore, paclitaxel showed more effective, wider‐spectrum anti‐tumor activity than cisplatin in this panel of 6 lung cancer xenografts. These findings support the potential utility of paclitaxel in the treatment of human lung cancer
Keywords: Paclitaxel, Human lung cancer, in vitro, in vivo, Anti‐tumor efficacy
Full Text
The Full Text of this article is available as a PDF (366.1 KB).
REFERENCES
- 1. ) Wani , M. C. , Taylor , H. L. , Wall , M. E. , Coggon , P. and McPhail , A. T.Plant anti tumor agents. IV. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia . J. Am. Chem. Soc. , 93 , 2325 – 2327 ( 1971. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Schiff , P. B. , Fant , J. and Horwitz , S. B.Promotion of microtubule assembly in vitro by taxol . Nature , 277 , 665 – 667 ( 1979. ). [DOI] [PubMed] [Google Scholar]
- 3. ) Schiff , P. B. and Horwitz , S. B.Taxol stabilizes micro‐tubules in mouse fibroblast cells . Proc. Natl. Acad. Sci. USA , 77 , 1561 – 1565 ( 1980. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. ) Holmes , E. C. , Livingston , R. and Turrisi , A. , III . Neoplasms of the thorax . In “ Cancer Medicine ” ed. Holland J. F. , Frei E., III , Bast R. C., Jr. , Kufe D. W. , Morton D. L. and Weichselbaum R. R. , pp. 1285 – 1337 ( 1993. ). Lea and Febiger; , Philadelphia, London . [Google Scholar]
- 5. ) Murphy , W. K. , Fossella , F. V. , Winn , R. J. , Shin , D. M. , Hynes , H. E. , Gross , H. M. , Davilla , E. , Leimert , J. , Dhingra , H. , Raber , M. N. , Krakoff , I. H. and Hong , W. K.Phase II study of taxol in patients with untreated advanced non‐small‐cell lung cancer . J. Natl. Cancer Inst. , 85 , 384 – 388 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Sekine , L , Nishiwaki , Y. , Watanabe , K. , Yoneda , S. , Saijo , N. and The East Japan Paclitaxel Study Group . Phase II study of 3‐hour infusion of paclitaxel in previously untreated non‐small cell lung cancer . Clin. Cancer Res. , 2 , 941 – 945 ( 1996. ). [PubMed] [Google Scholar]
- 7. ) Edelman , M. J. and Gandara , D. R.Promising new agents in the treatment of non–small cell lung cancer . Cancer Chemother. Pharmacol , 37 , 385 – 393 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 8. ) Rose , W. C.Taxol: a review of its preclinical in vivo antitumor activity . Anti–Cancer Drugs , 3 , 311 – 321 ( 1992. ). [PubMed] [Google Scholar]
- 9. ) Kelner , M. J. , Mcmorris , T. C. , Estes , L. , Starr , R. , Samson , K. , Varki , N. and Taetle , R.Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents , Anticancer Res. , 15 , 867 – 872 ( 1995. ). [PubMed] [Google Scholar]
- 10. ) Monks , A. , Scudiero , D. , Skehan , P. , Shoemaker , R. , Paull , K. , Vistica , D. , Hose , C. , Langley , J. , Cronise , P. , Vaigro‐Wolff , A. , Gray–Goodrich , M. , Campbell , H. , Mayo , J. , Boyd , M.Feasibility of a high–flux anticancer drug screen using a diverse panel of cultured human tumor cell lines . J. Natl. Cancer Inst , 83 , 757 – 766 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 11. ) Yamori , T.A human cell line panel for screening anti‐cancer drugs . Jpn. J. Cancer Chemother. , 24 , 129 – 135 ( 1997. ) ( in Japanese ). [PubMed] [Google Scholar]
- 12. ) Stinson , S. F. , Alley , M. C , Kopp , W. C. , Fiebig , H.–H. , Mullendore , L. A. , Pittman , A. F. , Kenney , S. , Keller , J. , Boyd , M. R , Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease‐oriented anticancer drug screen , Anticancer Res. , 12 , 1035 – 1053 ( 1992. ). [PubMed] [Google Scholar]
- 13. ) Skehan , P. , Storeng , R. , Scudiero , D. , Monks , A. , McMahon , J. , Vistica , D. , Warren , J. T. , Bokesch , H. , Kenney , S. and Boyd , M. R.New colorimetric cytotoxicity assay for anticancer‐drug screening . J. Natl. Cancer Inst. , 82 , 1107 – 1112 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 14. ) Fujimoto , S.Schedule dependency of IV‐paclitaxel against SC‐M109 mouse lung cancer . Jpn. J. Cancer Chemother. , 21 , 671 – 677 ( 1994. ). ( in Japanese ). [PubMed] [Google Scholar]
- 15. ) Perego , P. , Giarola , M. , Righetti , S. C. , Supino , R. , Caserini , C. , Delia , D. , Pierotti , M. A. , Miyashita , T. , Reed , J. C. and Zunino , F.Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell system . Cancer Res. , 56 , 556 – 562 ( 1996. ). [PubMed] [Google Scholar]
- 16. ) Wahl , A. F. , Donaldson , K. L. , Fairchild , C. , Lee , F. Y. , Foster , S. A. , Demers , G. W. and Galloway , D. A.Loss of normal p53 function confers sensitization of taxol by increasing G2/M arrest and apoptosis . Nat. Med. , 2 , 72 – 79 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 17. ) Weinstein , J. N. , Myers , T. G. , O'Connor , P. M. , Friend , S. H. , FornaceJr. , A. J. , Kohn , K. W. , Fojo , T. , Bates , S. E. , Rubinstein , L. V. , Anderson , N. L. , Buolamwini , J. K. , van Osdol , W. W. , Monks , A. P. , Scudiero , D. A. , Sausville , E. A. , Zaharevitz , D. W. , Bunow , B. , Viswanadhan , V. N. , Johnson , G. S. , Wittes , R. E. and Paull , K. D.An information–intensive approach to the molecular pharmacology of cancer . Science , 275 , 343 – 349 ( 1997. ). [DOI] [PubMed] [Google Scholar]
- 18. ) Engblom , P. , Rantanen , V. , Kulmala , J. and Grenman , S.Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96–well plate clonogenic assay . Anticancer Res. , 16 , 1743 – 1748 ( 1996. ). [PubMed] [Google Scholar]
- 19. ) Ohtsu , T. , Sasaki , Y. , Tamura , T. , Miyata , Y. , Nakanomyo , H. , Nishiwaki , Y. and Saijo , N.Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3‐hour infusion versus a 24‐hour infusion . Clin. Cancer Res. , 1 , 599 – 606 ( 1995. ). [PubMed] [Google Scholar]
- 20. ) Kubota , T. , Matsuzaki , S. W. , Hoshiya , Y. , Watanabe , M. , Kitajima , M. , Asanuma , F. , Yamada , Y. and Koh , J.Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice . J. Surg. Oncol , 64 , 115 – 121 ( 1997. ). [DOI] [PubMed] [Google Scholar]
- 21. ) Riondel , J. , Jacrot , M. , Picot , F. , Beriel , H. , Mouriquand , C. and Potier , P.Therapeutic response to taxol of six human tumors xenografted into nude mice . Cancer Chemother. Pharmacol , 17 , 137 – 142 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 22. ) Sternberg , C. N. , Sordillo , P. P. , Cheng , E. , Chuang , Y. J. and Niedzwiecki , D.Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice . Am. J. Clin. Oncol , 10 , 219 – 221 ( 1987. ). [DOI] [PubMed] [Google Scholar]